Citations

Mayo Clinic

Clear

12606 citation(s) found for "Vu, John A".

Texture Features from Mammographic Images and Risk of Breast Cancer
Carston, Michael J., Heine, John , Scott, Christopher G. , Brandt, Kathy R., Sellers, Thomas A. , Vachon, Celine M. , Cerhan, James R. , Manduca, Armando , Pankratz, V. Shane , Vachon, Celine M. , Cerhan, James R , Scott, Christopher

Cancer Epidemiology, Biomarkers & Prevention | March 9, 2009 | Volume: 18 | Issue: 3 | Pages: 837-845

10.1158/1055-9965.epi-08-0631 | PMID 19258482 Get It

AbstractMammographic percent density (PD) is a strong risk factor for breast cancer, but there has been relatively little systematic evaluation of other features in mammographic images that might additionally predict breast cancer risk. We evaluated the association of a large number of image texture features with risk of breast cancer using a clinic-based case-control study of digitized film mammograms, all with screening mammograms before breast cancer diagnosis. The sample was split into training (123 cases and 258 controls) and validation (123 cases and 264 controls) data sets. Age-adjusted and body mass index (BMI)–adjusted odds ratios (OR) per SD change in the feature, 95% confidence intervals, and the area under the receiver operator characteristic curve (AUC) were obtained using logistic regression. A bootstrap approach was used to identify the strongest features in the training data set, and results for features that validated in the second half of the sample were reported using the full data set. The mean age at mammography was 64.0 ± 10.2 years, and the mean time from mammography to breast cancer was 3.7 ± 1.0 (range, 2.0-5.9 years). PD was associated with breast cancer risk (OR, 1.49; 95% confidence interval, 1.25-1.78). The strongest features that validated from each of several classes (Markovian, run length, Laws, wavelet, and Fourier) showed similar ORs as PD and predicted breast cancer at a similar magnitude (AUC = 0.58-0.60) as PD (AUC = 0.58). All of these features were automatically calculated (unlike PD) and measure texture at a coarse scale. These features were moderately correlated with PD (r = 0.39-0.76), and after adjustment for PD, each of the features attenuated only slightly and retained statistical significance. However, simultaneous inclusion of these features in a model with PD did not significantly improve the ability to predict breast cancer. (Cancer Epidemiol Biomarkers Prev 2009;18(3):837–45)
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project
Carson, Kenneth R. , Evens, Andrew M. , Richey, Elizabeth, Focosi, Daniele , Seymour, John F. , Laubach, Jacob P. , Bawn, Susie D., Gordon, Leo I. , Furman, Richard R. , Zelenetz, Andrew D. , Mamtani, Ronac , Raisch, Dennis W., Dorshimer, Gary W., Rosen, Steven T. , Muro, Kenji , Gottardi-Littell, Numa R., Talley, Robert L., Green, David , Major, Eugene O. , Bennett, Charles L. , Habermann, Thomas M. , Winter, Jane N. , Vose, Julie M. , Sartor, Oliver , Gordon, Leo I , Zelenetz, Andrew D , Evens, Andrew M , Focosi, Daniele

Blood | March 6, 2009 | Volume: 113 | Issue: 20 | Pages: 4834-4840

10.1182/blood-2008-10-186999 | PMID 19264918 Get It

Rituximab improves outcomes for persons with lymphoproliferative disorders and is increasingly used to treat immune-mediated illnesses. Recent reports describe 2 patients with systemic lupus erythematosus and 1 with rheumatoid arthritis who developed progressive multifocal leukoencephalopathy (PML) after rituximab treatment. We reviewed PML case descriptions among patients treated with rituximab from the Food and Drug Administration, the manufacturer, physicians, and a literature review from 1997 to 2008. Overall, 52 patients with lymphoproliferative disorders, 2 patients with systemic lupus erythematosus, 1 patient with rheumatoid arthritis, 1 patient with an idiopathic autoimmune pancytopenia, and 1 patient with immune thrombocytopenia developed PML after treatment with rituximab and other agents. Other treatments included hematopoietic stem cell transplantation (7 patients), purine analogs (26 patients), or alkylating agents (39 patients). One patient with an autoimmune hemolytic anemia developed PML after treatment with corticosteroids and rituximab, and 1 patient with an autoimmune pancytopenia developed PML after treatment with corticosteroids, azathioprine, and rituximab. Median time from last rituximab dose to PML diagnosis was 5.5 months. Median time to death after PML diagnosis was 2.0 months. The case-fatality rate was 90%. Awareness is needed of the potential for PML among rituximab-treated persons.
Microbiologic Diagnosis of Prosthetic Shoulder Infection by Use of Implant Sonication
Piper, Kerryl E., Jacobson, Melissa, Cofield, Robert H. , Sperling, John W. , Osmon, Douglas R. , McDowell, Andrew , Patrick, Sheila , Steckelberg, James M., Mandrekar, Jayawant N. , Sampedro, Marta Fernández , Patel, Robin , Sánchez‐Sotelo, Joaquín , Patel, Robin

Journal of Clinical Microbiology | March 5, 2009 | Volume: 47 | Issue: 6 | Pages: 1878-1884

10.1128/jcm.01686-08 | PMID 19261785 Get It

ABSTRACT We recently described a sonication technique for the diagnosis of prosthetic knee and hip infections. We compared periprosthetic tissue culture to implant sonication followed by sonicate fluid culture for the diagnosis of prosthetic shoulder infection. One hundred thirty-six patients undergoing arthroplasty revision or resection were studied; 33 had definite prosthetic shoulder infections and 2 had probable prosthetic shoulder infections. Sonicate fluid culture was more sensitive than periprosthetic tissue culture for the detection of definite prosthetic shoulder infection (66.7 and 54.5%, respectively; P = 0.046). The specificities were similar (98.0% and 95.1%, respectively; P = 0.26). Propionibacterium acnes was the commonest species detected among culture-positive definite prosthetic shoulder infection cases by periprosthetic tissue culture (38.9%) and sonicate fluid culture (40.9%). All subjects from whom P. acnes was isolated from sonicate fluid were male. We conclude that sonicate fluid culture is useful for the diagnosis of prosthetic shoulder infection.
Targeting Bone Remodeling for the Treatment of Osteoporosis: Summary of the Proceedings of an ASBMR Workshop
Bilezikian, John P. , Bellido, Teresita , Khosla, Sundeep , Martin, Jack W. , Recker, Robert R. , Heaney, Robert P., Seeman, Ego , Papapoulos, Socrates E. , Goldring, Steven R., Matsumoto, Toshio , Khosla, Sundeep

Journal of Bone and Mineral Research | March 4, 2009 | Volume: 24 | Issue: 3 | Pages: 373-385

10.1359/jbmr.090105 | PMID 19260805 Get It

The Tamoxifen Metabolite, Endoxifen, Is a Potent Antiestrogen that Targets Estrogen Receptor α for Degradation in Breast Cancer Cells
Wu, Xianglin, Hawse, John R. , Subramaniam, Malayannan , Spelsberg, Thomas C., Goetz, Matthew P. , Ingle, James N.

Cancer Research | February 25, 2009 | Volume: 69 | Issue: 5 | Pages: 1722-1727

10.1158/0008-5472.can-08-3933 | PMID 19244106 Get It

Abstract Tamoxifen has been the most important therapeutic agent for the treatment of estrogen receptor (ER)-positive breast cancer for the past three decades. Tamoxifen is extensively metabolized by cytochrome P450 enzymes, and recent in vivo studies have shown that women with genetically impaired cytochrome P450 2D6 have reduced production of endoxifen and a higher risk of breast cancer recurrence. Despite these observations, the contribution of endoxifen to the overall drug effectiveness of tamoxifen remains uncertain. Here, we provide novel evidence that endoxifen is a potent antiestrogen that functions in part by targeting ERα for degradation by the proteasome in breast cancer cells. Additionally, we show that endoxifen blocks ERα transcriptional activity and inhibits estrogen-induced breast cancer cell proliferation even in the presence of tamoxifen, N-desmethyl-tamoxifen, and 4-hydroxytamoxifen. All of the effects of endoxifen are concentration dependent and do not occur at concentrations observed in human CYP2D6 poor metabolizers. These results support the theory that endoxifen is the primary metabolite responsible for the overall effectiveness of tamoxifen in the treatment of ER-positive breast cancer. [Cancer Res 2009;69(5):1722–7]
Age at intracranial aneurysm rupture among generations
Woo, Daniel, Hornung, R W, Sauerbeck, Laura, Brown, Robert D. , Meissner, Irene, Foroud, Tatiana, Broderick, Joseph , Derdeyn, Colin P. , Hankey, Graeme J. , Tirschwell, David , Huston, John , Hankey, Graeme J , Derdeyn, Colin P

Neurology | February 23, 2009 | Volume: 72 | Issue: 8 | Pages: 695-698

10.1212/01.wnl.0000342999.99907.fd | PMID 19237697 Get It

Greater Rupture Risk for Familial as Compared to Sporadic Unruptured Intracranial Aneurysms
Brown, Robert D., Sauerbeck, Laura, Hornung, Richard, Woo, Daniel, Anderson, Craig S. , Kleindorfer, Dawn , Flaherty, Matthew L. , Meissner, Irene, Charles, Elijah, Moomaw, J., Connolly, E. Sander , Derdeyn, Colin P. , Hankey, Graeme J. , Tirschwell, David , Broderick, Joseph P. , Huston, John , Rouleau, Guy Armand , Foroud, Tatiana , Hankey, Graeme J , Derdeyn, Colin P

Stroke | February 19, 2009 | Volume: 40 | Issue: 6 | Pages: 1952-1957

10.1161/strokeaha.108.542571 | PMID 19228834 Get It

Background and Purpose— The risk of intracranial aneurysm (IA) rupture in asymptomatic members of families who have multiple affected individuals is not known. Methods— First-degree unaffected relatives of those with a familial history of IA who had a history of smoking or hypertension but no known IA were offered cerebral MR angiography (MRA) and followed yearly as part of a National Institute of Neurological Diseases and Stroke-funded study of familial IA (Familial Intracranial Aneurysm [FIA] Study). Results— A total of 2874 subjects from 542 FIA Study families were enrolled. After study enrollment, MRAs were performed in 548 FIA Study family members with no known history of IA. Of these 548 subjects, 113 subjects (20.6%) had 148 IAs by MRA of whom 5 subjects had IA ≥7 mm. Two subjects with an unruptured IA by MRA/CT angiography (3-mm and 4-mm anterior communicating artery) subsequently had rupture of their IA. This represents an annual rate of 1.2 ruptures per 100 subjects (1.2% per year; 95% CI, 0.14% to 4.3% per year). None of the 435 subjects with a negative MRA have had a ruptured IA. Survival curves between the MRA-positive and -negative cohorts were significantly different ( P =0.004). This rupture rate of unruptured IA in the FIA Study cohort of 1.2% per year is approximately 17 times higher than the rupture rate for subjects with an unruptured IA in the International Study of Unruptured Aneurysm Study with a matched distribution of IA size and location 0.069% per year. Conclusions— Small unruptured IAs in patients from FIA Study families may have a higher risk of rupture than sporadic unruptured IAs of similar size, which should be considered in the management of these patients.
Interposition graft with polytetrafluoroethylene for mesenteric and portal vein reconstruction after pancreaticoduodenectomy
Stauffer, John , Dougherty, Marjorie K., Kim, G.P., Nguyen, Justin H. , A Stauffer, John

British Journal of Surgery | February 17, 2009 | Volume: 96 | Issue: 3 | Pages: 247-252

10.1002/bjs.6483 | PMID 19224515 Get It

Abstract Background Portal vein–superior mesenteric vein resection is frequently required after surgical resection of tumours of the pancreas head. The ideal graft for portal vein reconstruction (PVR) remains undefined. Methods Between May 2000 and July 2007, 28 patients had portal vein–superior mesenteric vein resection and PVR during pancreaticoduodenectomy. Their clinical reports were reviewed retrospectively with specific attention to the methods of PVR and outcomes. Results Ten patients had PVR with primary anastomosis, seven had PVR with autologous vein, one had a polytetrafluoroethylene (PTFE) patch, one did not have PVR and nine had PVR with a PTFE interposition graft. There was no infection after PTFE grafting. Six patients had PVR thrombosis after surgery: four after primary anastomosis, one after interposition PTFE and one after vein repair. Conclusion PTFE appeared to be an effective and safe option as an interposition graft for portomesenteric venous reconstruction after pancreaticoduodenectomy.
Verbal learning and memory in patients with dementia with Lewy bodies or Parkinson's disease with dementia
Filoteo, J. Vincent , Salmon, David P. , Schiehser, Dawn M. , Kane, Amy E., Hamilton, Joanne M., Rilling, Laurie M., Lucas, John A. , Zizak, Vanessa, Galasko, Douglas

Journal of Clinical and Experimental Neuropsychology | February 17, 2009 | Volume: 31 | Issue: 7 | Pages: 823-834

10.1080/13803390802572401 | PMID 19221922 Get It

SUPERFICIAL SIDEROSIS: SEALING THE DEFECT
Kumar, Neeraj , Lane, John I. , Piepgras, David G.

Neurology | February 16, 2009 | Volume: 72 | Issue: 7 | Pages: 671-673

10.1212/01.wnl.0000342457.22536.af | PMID 19221303 Get It